Varuby (rolapitant): Reviews and patient testimonials
Medication indications
Varuby 90 mg film-coated tablets- Summary of Product Characteristics
Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults
Varuby is given as part of combination therapy.
Route of administration: Oral
Molecule: rolapitant
Patients' opinions on Varuby
In brief
General satisfaction level: Be the first to evaluate
Treatment's effectiveness: Be the first to evaluate
Ease of use: Be the first to evaluate
Adherence to prescription: Be the first to evaluate
Detected side effects: Be the first to evaluate
Improvement in the quality of life: Be the first to evaluate
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Never
10 = Always
1 = Not at all important
10 = Extremely important
1 = Not at all satisfied
10 = Extremely satisfied
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.